Table 3.
The comparison of anthropometric and biochemical parameters and clinical stage in the PTC patients depending on the presence/absence of the metabolic syndrome.
| Patients without the metabolic syndrome n = 109 95 women, 14 men (mean ± SD; median) |
Patients with the metabolic syndrome n = 68 56 women, 12 men (mean ± SD; median) |
p | |
|---|---|---|---|
| Age | 47.21 ± 14.45; 46 | 57.06 ± 11.54; 59.5 | <0.001 |
| BMI (kg/m2) | 26.19 ± 5.06; 26.15 | 31.11 ± 4.52; 31.06 | <0.001 |
| Waist (cm) | 86.77 ± 13.75; 87 | 101.70 ± 11.96; 101 | <0.001 |
| WHR | 0.83 ± 0.09; 0.82 | 0.91 ± 0.08; 0.90 | <0.001 |
| Glucose (mg/dL) | 117.80 ± 22.30; 114 | 125.18 ± 29.22; 119 | NS |
| TGs (mg/dL) | 133.22 ± 67.16; 112 | 187.07 ± 61.44; 178 | <0.001 |
| HDL (mg/dL) | 62.28 ± 18.32; 58 | 49.28 ± 16.65; 44.5 | <0.001 |
| Cholesterol (mg/dL) | 281.22 ± 122.56; 231 | 271.04 ± 119.41; 230 | NS |
| HOMA-IR | 1.14 ± 0.65; 0.97 | 1.68 ± 1.25; 1.41 | <0.001 |
| Adiponectin (μg/mL) | 15.66 ± 6.44; 15.0 | 13.64 ± 6.05; 13.0 | <0.001 |
| Leptin (ng/mL) | 14.14 ± 10.26; 10.98 | 26.08 ± 24.52; 21.5 | <0.001 |
| Chemerin (ng/mL) | 213.22 ± 49.22; 209 | 243.75 ± 44.79; 236 | <0.001 |
| Vitamin D (nmol/L) | 67.53 ± 24.05; 61 | 63.02 ± 21.25; 60 | NS |
| IL-6 (pg/mL) | 2.49 ± 0.76; 2.29 | 3.01 ± 1.28; 2.83 | <0.001 |
| N (%) of patients with microcarcinomas | 62 (56.88) | 32 (47.06) | NS |
| N (%) of patients with | |||
| Stage I | 94 (86.24) | 50 (73.53) | <0.05 |
| Stage II | 14 (12.84) | 17 (25) | <0.05 |
| Stage III | 1 (0.92) | 0 | |
| Stage IV | 0 | 1 (1.47) |
NS = not significant.